Moody Aldrich Partners LLC Purchases New Position in Evolent Health, Inc. (NYSE:EVH)

Moody Aldrich Partners LLC acquired a new stake in shares of Evolent Health, Inc. (NYSE:EVH - Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 50,259 shares of the technology company's stock, valued at approximately $1,421,000.

Other large investors also recently added to or reduced their stakes in the company. Principal Financial Group Inc. increased its position in shares of Evolent Health by 3.2% during the second quarter. Principal Financial Group Inc. now owns 15,594 shares of the technology company's stock worth $298,000 after acquiring an additional 480 shares during the period. Ascent Group LLC raised its position in Evolent Health by 2.8% during the 1st quarter. Ascent Group LLC now owns 20,330 shares of the technology company's stock valued at $667,000 after purchasing an additional 550 shares in the last quarter. SeaCrest Wealth Management LLC raised its position in Evolent Health by 6.3% during the 2nd quarter. SeaCrest Wealth Management LLC now owns 10,200 shares of the technology company's stock valued at $195,000 after purchasing an additional 600 shares in the last quarter. American International Group Inc. lifted its holdings in shares of Evolent Health by 1.2% in the 1st quarter. American International Group Inc. now owns 55,402 shares of the technology company's stock worth $1,817,000 after buying an additional 640 shares during the period. Finally, Arizona State Retirement System grew its position in shares of Evolent Health by 2.3% during the 2nd quarter. Arizona State Retirement System now owns 29,083 shares of the technology company's stock worth $556,000 after buying an additional 649 shares in the last quarter.

Evolent Health Stock Up 1.6 %

Shares of Evolent Health stock traded up $0.36 during trading on Thursday, reaching $22.76. The company's stock had a trading volume of 2,244,699 shares, compared to its average volume of 1,622,091. Evolent Health, Inc. has a 1-year low of $17.98 and a 1-year high of $35.00. The company has a 50-day simple moving average of $28.49 and a two-hundred day simple moving average of $25.42. The company has a quick ratio of 1.08, a current ratio of 1.08 and a debt-to-equity ratio of 0.57. The company has a market cap of $2.65 billion, a price-to-earnings ratio of -18.21 and a beta of 1.56.

Evolent Health (NYSE:EVH - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The technology company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.09. Evolent Health had a positive return on equity of 8.47% and a negative net margin of 3.16%. The business had revenue of $647.10 million during the quarter, compared to the consensus estimate of $636.46 million. During the same quarter last year, the company earned $0.06 earnings per share. The company's quarterly revenue was up 37.9% on a year-over-year basis. As a group, equities analysts forecast that Evolent Health, Inc. will post 0.86 earnings per share for the current year.

Insiders Place Their Bets

In other Evolent Health news, COO Emily Ann Rafferty sold 8,861 shares of the firm's stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $30.00, for a total value of $265,830.00. Following the completion of the transaction, the chief operating officer now owns 63,408 shares of the company's stock, valued at approximately $1,902,240. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Evolent Health news, COO Emily Ann Rafferty sold 8,861 shares of the business's stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $30.00, for a total transaction of $265,830.00. Following the sale, the chief operating officer now owns 63,408 shares in the company, valued at approximately $1,902,240. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Seth Blackley sold 187,904 shares of the firm's stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $30.00, for a total value of $5,637,120.00. Following the completion of the transaction, the chief executive officer now owns 411,924 shares of the company's stock, valued at approximately $12,357,720. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 307,291 shares of company stock valued at $9,290,385. Insiders own 1.60% of the company's stock.

Wall Street Analyst Weigh In

EVH has been the subject of several recent research reports. Royal Bank of Canada restated an "outperform" rating and issued a $42.00 price objective on shares of Evolent Health in a report on Tuesday, October 8th. Truist Financial reaffirmed a "buy" rating and issued a $33.00 price target on shares of Evolent Health in a research report on Tuesday, August 27th. KeyCorp initiated coverage on shares of Evolent Health in a report on Friday, October 11th. They set an "overweight" rating and a $35.00 price objective on the stock. JPMorgan Chase & Co. upped their target price on Evolent Health from $36.00 to $45.00 and gave the stock an "overweight" rating in a report on Monday, August 19th. Finally, Stephens reiterated an "overweight" rating and issued a $42.00 price target on shares of Evolent Health in a report on Tuesday, July 30th. Eleven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $39.30.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.